790 studies found for:    Open Studies | "Lymphoma, Non-Hodgkin"
Show Display Options
Rank Status Study
21 Recruiting A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: Obinutuzumab;   Drug: CC-122
22 Recruiting Molecular and Whole-body MR Imaging in Lymphomas
Conditions: Lymphoma;   Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Other: 68Ga-DOTANOC PET/CT; Diffusion weighted MRI
23 Recruiting Phase III Copanlisib in Rituximab-refractory iNHL
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: BAY No. 80 6946;   Drug: Placebo
24 Not yet recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
25 Recruiting Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Rituximab
26 Recruiting Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Conditions: Multiple Myeloma;   Lymphoma, Non-Hodgkin
Interventions: Drug: XM02 Filgrastim;   Drug: Filgrastim;   Procedure: Apheresis;   Drug: Plerixafor
27 Recruiting Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Leukemia Acute Myeloid;   Lymphoma, Non-Hodgkin;   Myelodysplastic Syndrome;   Immunologic Deficiency Syndromes
Interventions: Biological: BPX-501 T cells and AP1903;   Drug: AP1903
28 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
29 Recruiting Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Conditions: MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention: Device: Graft Manipulation (CD34+ Selection)
30 Unknown  Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
31 Recruiting Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Lymphoid Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Rituximab;   Drug: Lenalidomid
32 Recruiting Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Drug: SD-101;   Radiation: Local Radiation
33 Recruiting Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Hematopoetic Myelodysplasia;   Leukemia, Myelogenous, Chronic;   Lymphoma, Non-Hodgkin
Intervention: Drug: Sitagliptin
34 Recruiting Tissue Collection for Studies of Lymph Cancer
Conditions: Hodgkin Disease;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Lymphomatoid Granulomatosis;   Leukemia-Lymphoma, Adult T-Cell
Intervention:
35 Recruiting Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Conditions: Myeloid Leukemia, Chronic;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes (MDS);   Lymphoma, Non-Hodgkin
Intervention: Biological: Conventional T cells (Tcon) and Regulatory T cells (Treg)
36 Recruiting Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
37 Recruiting Study of Lymphoma in Asia
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myleoma;   Lympocytic, Follicular;   Leukemia;   Hodgkin Lymphoma
Intervention:
38 Unknown  Functional Assessment of Cancer Therapy - Bone Marrow Transplant
Conditions: Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Other: Database
39 Recruiting FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Conditions: Lymphoma;   Lymphoma, Non-Hodgkin;   Large B Cell Diffuse Lymphoma
Interventions: Procedure: FLT-PET/CT;   Procedure: FDG-PET/CT;   Drug: FLT
40 Recruiting BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BI 836826

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years